CN103954757A - Method for evaluating colorectal cancer through TEAD4 positive cell nucleus expression conditions - Google Patents
Method for evaluating colorectal cancer through TEAD4 positive cell nucleus expression conditions Download PDFInfo
- Publication number
- CN103954757A CN103954757A CN201410169571.8A CN201410169571A CN103954757A CN 103954757 A CN103954757 A CN 103954757A CN 201410169571 A CN201410169571 A CN 201410169571A CN 103954757 A CN103954757 A CN 103954757A
- Authority
- CN
- China
- Prior art keywords
- tead4
- minutes
- positive
- nucleus
- colorectal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
Abstract
The invention relates to a method for evaluating colorectal cancer through TEAD4 positive cell nucleus expression conditions. The method comprises the following steps: preparing a tumor tissue chip, performing immunohistochemical experiment and immunoreactive score, grouping according to the immunoreactive score; and finally, dividing patients into a TEAD4 positive cell nucleus expression group and a TEAD4 negative cell nucleus expression group according to TEAD4 cell nucleus staining conditions, and analyzing clinical features and differences of overall survival of the two groups of patients by using a statistical method. According to the method for evaluating the clinical features and overall prognosis of the colorectal cancer patients through colorectal cancer immunological indicator TEAD4 positive cell nucleus expression conditions, the clinical features and prognosis information of the patients can be directly determined according to the TEAD4 positive cell nucleus expression conditions in tumor tissues of the colorectal cancer patients.
Description
Technical field
The present invention relates to a kind of method, specifically, is the method for by TEAD4 nucleus positive expression situation, colorectal cancer being evaluated about a kind of.
Background technology
Knot, the carcinoma of the rectum are the common malignant tumours of China.Account for the 4th of China's malignant tumour, and have the trend of rising.Chinese's knot, the carcinoma of the rectum and westerner relatively have 3 epidemics: 1. the carcinoma of the rectum is higher than the colon cancer incidence of disease, approximately 1.5: 1; 2. Low Rectal proportion in the carcinoma of the rectum is high, accounts for 75%, and most of carcinoma of the rectum can be touched when digital rectal examination; 3. young people (< 30 years old) Proportion of patients is higher, accounts for 15%.But in recent decades,, along with the raising of living standards of the people and the change of dietary structure, colon cancer ratio also increases gradually.But about a kind of method of the Clinical symptoms of colorectal cancer patients and prognosis being evaluated by colorectal cancer amynologic index TEAD4 nucleus positive expression situation, yet there are no report.
Summary of the invention
The object of the invention is for deficiency of the prior art, a kind of method of the Clinical symptoms of colorectal cancer patients and prognosis being evaluated by colorectal cancer amynologic index TEAD4 nucleus positive expression situation is provided.
For achieving the above object, the technical scheme that the present invention takes is:
A method of colorectal cancer being evaluated by TEAD4 nucleus positive expression situation, comprises the steps:
(1), make tumor tissues wax stone;
(2), according to the position of tumor tissues in the wax stone of HE dyeing determining step (1) gained, choose the central part of tumor tissues wherein and make organization chip;
(3), organization chip, positive control and the negative control of step (2) gained are carried out to immunohistochemical staining; Wherein said positive control is used and has turned out to be the organization chip that the positive tumor cell tissue organizing makes; Described negative control is used identical organization chip;
(4), the conventional dewaxing of organization chip, aquation;
(5), microwave antigen retrieval;
(6), deactivating endogenous peroxydase;
(7), sealing nonspecific proteins;
(8), drip primary antibodie
TEAD4 primary antibodie is diluted by 1: 50 by 5% Bovine Serum Albumin in Aqueous Solution, as for 4 ℃ of overnight incubation in wet box; In negative control, with PBS damping fluid, replace primary antibodie;
(9), rewarming is 45 minutes;
(10), dripping two resists;
(11), DAB colour developing;
(12), haematoxylin is redyed;
(13), dehydration and transparent;
(14), mounting;
(15), interpretation of result:
Positive signal is brown yellow granule, with come card optical microscope, under 200 times of enlargement factors, five pictures is taken to by each tissue site of above-mentioned gained, the nuclear color intensity of TEAD4 positive staining in recordable picture;
If the nucleus that does not have brown color to dye, immunity scoring is 0 minute;
If the nuclear intensity of positive staining is light brown, immunity scoring is 1 minute;
If the nuclear intensity of positive staining is that moderate is brown, immunity scoring is 2 minutes;
If the nuclear intensity of positive staining is dark-brown, immunity scoring is 3 minutes;
(16), according to the immunity of step (15) gained, divide into groups, immunity scoring is 0,1,2 is classified as one group and is negative a group of expressing of TEAD4 nucleus, and immunity scoring is 3 one group of a group of being TEAD4 nucleus positive expression that is classified as;
(17), utilize Spss11.0 analysis software and Graph Pad prism5 mapping software, according to the grouping of step (16) to TEAD4 nucleus positive and negative expression and patient's Clinical symptoms and the relation of overall survival analyze, judge the nucleus expression of TEAD4 and the prognosis effect of colorectal cancer patients.
Described, the microwave antigen retrieval that step (5) is described, being about to histotomy is dipped in the antigen retrieval liquid of sodium citrate, trisodium citrate and pure water preparation, in micro-wave oven, high fire screen heating is 3 minutes, then in, low fire screen heating is 4 minutes * 2 times, cooling under room temperature after taking out, with the washing of PBS damping fluid, 5 minutes * 3 times.
The deactivating endogenous peroxydase described, step (6) is described, with 30% hydrogen peroxide and methyl alcohol by the deactivation liquid being made at 1: 9, histotomy is immersed in deactivation liquid to 30 minutes, after deactivating endogenous peroxydase, with the washing of PBS damping fluid, 5 minutes * 3 times.
Described, the described sealing nonspecific proteins of step (7) is about to histotomy scrub, and the confining liquid that drips 50 microlitres on every histotomy is 5% BSA aqueous solution, hatches sealing heterogenetic antigen 30 minutes.
Described, the described anti-soon section of dropping two of step (10) is inserted in wet box, with filter paper, tissue moisture is around sucked, the A liquid that every histotomy drips in the universal immunologic combined detection reagent kit of anti-rabbit/mouse is one, horseradish peroxidase polymkeric substance, under room temperature, hatches half an hour.
The invention has the advantages that: a kind of method of the Clinical symptoms of colorectal cancer patients and overall prognosis being evaluated by colorectal cancer amynologic index TEAD4 nucleus positive expression situation of invention, according to the situation of TEAD4 nucleus positive expression in colorectal cancer patients tumor tissues, can directly determine patient's Clinical symptoms and prognosis information.
Accompanying drawing explanation
Fig. 1, under 200 and 400 enlargement factors, normal structure TEAD4 immunity scoring is 0 minute;
Fig. 2, under 200 and 400 enlargement factors, tumor tissues TEAD4 immunity scoring is 0 minute;
Fig. 3, under 200 and 400 enlargement factors, tumor tissues TEAD4 immunity scoring is 1 minute;
Fig. 4, under 200 and 400 enlargement factors, tumor tissues TEAD4 immunity scoring is 2 minutes;
Fig. 5, tumor tissues TEAD4 immunity scoring 3 minutes under 200 and 400 enlargement factors;
The graph of a relation of Fig. 6, life cycle and overall survival.
Embodiment
Below in conjunction with accompanying drawing, embodiment provided by the invention is elaborated.
In the embodiment of the present invention, the wax stone of 426 Colorectal Carcinomas used is all from Shanghai Communications University's attached Xinhua Hospital knot anorectum disease surgery.Xinhua Hospital Ethics Committee has been passed through in this experiment, and every patient has signed Informed Consent Form.
Immunohistochemical method, with reference to Wang Guanghui Identification of MXRA5as a novel tissue biomarker for colorectal cancer progression in 2013.
Mapping software used is Graph Pad prism5, and analysis software is Spss11.0.
In embodiments of the invention, reagent used is in Table 1, and main experimental apparatus and consumptive material be in Table 2, test reagent preparation used in Table 3.
Table 1 experiment reagent
Table 2 experimental apparatus and consumptive material
The preparation of table 3 reagent
embodiment 1
A method of the prognosis of colorectal cancer patients being evaluated by colorectal cancer amynologic index TEAD4 nucleus positive expression amount, specifically comprises the steps:
(1), first, 426 colorectal cancer tumor tissues samples of excision are carried out to paraffin embedding, make the wax stone of 426 colorectal cancer tumor tissues;
(2), then, according to HE, organization type is determined in dyeing, chooses tumor tissues and is made into five organization chips by Shanghai Biochip Co., Ltd, has 86 tumor tissues sites on every chip;
By the organization chip of above-mentioned steps (2) immunohistochemical experiment gained at come card optical microphotograph Microscopic observation, choose normal structure and tumour middle position is taken, under 200 and 400 times, observe respectively, can find out the TEAD4 expression that is negative in the nucleus of normal structure, specifically as shown in Figure 1; TEAD4 is in the expression that is negative of Partial tumors nucleus, specifically as shown in Figure 2,3, 4; TEAD4 is at Partial tumors nucleus positive expression, specifically as shown in Figure 5.
In sum, the nuclear positive expression of TEAD4 is very special, all express among tumour cell, there is not obvious mesenchyma stroma of tumors tissue staining, thereby this experiment can obtain the nuclear positive expression situation of TEAD4 more accurately, thereby carry out clinical data below and the analysis of overall survival, result is accurately credible, be that the nuclear positive staining of TEAD4 mainly concentrates in tumour cell, in different tumor tissues, TEAD4 nucleus positive expression amount is different;
(3), the wax stone of organization chip is made to the serial section of 4 μ m, the histotomy of gained is placed on metallochromy frame, be positioned in 60 ℃ of baking ovens roasting sheet 60 minutes to surperficial paraffin and melt;
(4), the conventional dewaxing of section aquation:
Histotomy is successively through dimethylbenzene washing 2 times, each 10 minutes, absolute ethanol washing 2 times, each 5 minutes, 95% alcohol washing 2 times, each 5 minutes, 75% alcohol washing 2 times, each 5 minutes, the paraffin on histotomy surface is taken off and abundant aquation, with tap water, rinsed section 1min afterwards, with PBS damping fluid, wash 1 minute * 3 times;
(5), microwave antigen retrieval:
Histotomy is dipped in the antigen retrieval liquid of sodium citrate, trisodium citrate and pure water preparation, and in micro-wave oven, high fire screen heating is 3 minutes, then in low fire screen heating 4 minutes * 2 times, cooling under room temperature after taking out, with the washing of PBS damping fluid, 5 minutes * 3 times;
(6), deactivating endogenous peroxydase:
The deactivation liquid being made into 30% hydrogen peroxide and methyl alcohol, is immersed in deactivation liquid 30 minutes by histotomy, after deactivating endogenous peroxydase, with the washing of PBS damping fluid, 5 minutes * 3 times;
(7), sealing nonspecific proteins:
By histotomy scrub, the confining liquid that drips 50 microlitres on every histotomy is 5% BSA aqueous solution, hatches sealing heterogenetic antigen 30 minutes;
(8), drip primary antibodie:
The primary antibodie dilution ratio of recommending according to antibody instructions is pressed 1: 50 dilution antibody by 5% Bovine Serum Albumin in Aqueous Solution, as for 4 ℃ of overnight incubation in wet box, by experimental design, using PBS damping fluid replacement primary antibodie as negative control, with known positive setup action positive control;
(9), second day by histotomy as for rewarming in 37 ℃ of baking ovens 45 minutes; The washing of PBS damping fluid, 10 minutes * 3 times;
(10), dripping two resists:
The universal immunologic combined detection reagent kit of anti-rabbit/mouse is hereinafter to be referred as two anti-kits, section is inserted in wet box, with filter paper, tissue moisture is around sucked, the A liquid that every histotomy drips in two anti-kits is one, horseradish peroxidase polymkeric substance, under room temperature, hatches half an hour;
(11), DAB colour developing:
The B liquid of two anti-kits in is DAB stoste is DBA damping fluid according to B liquid with C liquid: the proportional arrangement that C liquid is 1: 50 becomes nitrite ion, every histotomy adds the nitrite ion of 70ul, control under the microscope developing time, observe and occur positive findings stopped reaction when obviously background is painted again, with distilled water flushing 10 minutes;
(12), redye:
Haematoxylin is redyed 30 seconds, distilled water flushing 10 minutes;
(13), dehydration and transparent:
By histotomy successively through 75% alcohol washing 2 times, each 5 minutes, 95% alcohol washing 2 times, each 5 minutes, absolute ethanol washing 2 times, each 5 minutes, dimethylbenzene washing 2 times, each 10 minutes;
(14), place 5min in fuming cupboard, make the dimethylbenzene volatilization on histotomy, then use neutral gum mounting, after mounting, in baking oven, place 1 hour, natural gum is solidified as early as possible;
(15), each tissue site of step (14) gained is carried out to picture shooting under come card optical microscope, enlargement factor is selected 200 times, and five pictures are taken by each tissue site, the nuclear color intensity of TEAD4 positive staining in recordable picture;
If the nucleus that does not have brown color to dye, immunity scoring is 0 minute;
If the nuclear intensity of positive staining is light brown, immunity scoring is 1 minute;
If the nuclear intensity of positive staining is that moderate is brown, immunity scoring is 2 minutes;
If the nuclear intensity of positive staining is dark-brown, immunity scoring is 3 minutes;
The scoring distribution situation of final 428 above-mentioned Colorectal Carcinomas is in Table 4:
The immunity scoring distribution situation of 428 Colorectal Carcinomas of table 4
(16), according to the immunity scoring of step (15), by immunity scoring be 0 minute, 1 minute and 2 minutes to be classified as one group be the negative expression group of TEAD4 nucleus, immunity scoring be 3 to be classified as one group be TEAD4 nucleus positive expression group;
(17), analyze the relation of TEAD4 nucleus positive expression and clinical characteristic and overall survival
Utilize the relation of Spss11.0 analysis software TEAD4 nucleus positive staining group and negative staining group and its Clinical symptoms, the results are shown in subordinate list 1, more easily there is the tumour of right hemicolon in the patient of TEAD4 nucleus positive expression group, and patient's TNM is by stages relatively late, more easily there is lymph node and the transfer of internal organs at a distance, and the high expressed of TEAD4 and patient's change of serum C EA, CA242 level raise obviously relevant, and the patient of the negative expression group of TEAD4 nucleus by stages relatively early, be not prone to lymph node and the transfer of internal organs at a distance.
Utilize Graph Pad prism5 mapping software, the survival of patients phase that following up a case by regular visits to of the negative expression group of TEAD4 nucleus in step (16) and TEAD4 nucleus positive expression group obtained is as horizontal ordinate, overall survival is mapped as ordinate, the results are shown in Figure 6, according to the relation analysis of the figure life cycle of gained and overall survival, judge the prognosis effect of TEAD4 nucleus positive expression amount and colorectal cancer patients.As can be seen from Figure 6, the patient's of TEAD4 nucleus positive expression prognosis is obviously worse than the negative patient who expresses of TEAD4 nucleus, i.e. the poor prognosis of higher TEAD4 nucleus positive expression and patient is closely related.The relation of concrete TEAD4 nucleus expression and the pre-Clinical symptoms of patient is in Table 5
The relation of table 5 TEAD4 nucleus expression and the pre-Clinical symptoms of patient
Claims (5)
1. a method of by TEAD4 nucleus positive expression situation, colorectal cancer being evaluated, is characterized in that, comprises the steps:
(1), make tumor tissues wax stone;
(2), according to the position of tumor tissues in the wax stone of HE dyeing determining step (1) gained, choose the central part of tumor tissues wherein and make organization chip;
(3), organization chip, positive control and the negative control of step (2) gained are carried out to immunohistochemical staining; Wherein said positive control is used and has turned out to be the organization chip that the positive tumor cell tissue organizing makes; Described negative control is used identical organization chip;
(4), the conventional dewaxing of organization chip, aquation;
(5), microwave antigen retrieval;
(6), deactivating endogenous peroxydase;
(7), sealing nonspecific proteins;
(8), drip primary antibodie
TEAD4 primary antibodie is pressed 1:50 dilution by 5% Bovine Serum Albumin in Aqueous Solution, as for 4 ℃ of overnight incubation in wet box; In negative control, with PBS damping fluid, replace primary antibodie;
(9), rewarming is 45 minutes;
(10), dripping two resists;
(11), DAB colour developing;
(12), haematoxylin is redyed;
(13), dehydration and transparent;
(14), mounting;
(15), interpretation of result:
Positive signal is brown yellow granule, with come card optical microscope, under 200 times of enlargement factors, five pictures is taken to by each tissue site of above-mentioned gained, the nuclear color intensity of TEAD4 positive staining in recordable picture;
If the nucleus that does not have brown color to dye, immunity scoring is 0 minute;
If the nuclear intensity of positive staining is light brown, immunity scoring is 1
Minute;
If the nuclear intensity of positive staining is that moderate is brown, immunity scoring is 2 minutes;
If the nuclear intensity of positive staining is dark-brown, immunity scoring is 3 minutes;
(16), according to the immunity of step (15) gained, divide into groups, immunity scoring is 0,1,2 is classified as one group and is negative a group of expressing of TEAD4 nucleus, and immunity scoring is 3 one group of a group of being TEAD4 nucleus positive expression that is classified as;
(17), utilize Spss11.0 analysis software and Graph Pad prism 5 mapping softwares, according to the grouping of step (16) to TEAD4 nucleus positive and negative expression and patient's Clinical symptoms and the relation of overall survival analyze, judge the nucleus expression of TEAD4 and the prognosis effect of colorectal cancer patients.
2. the method for claim 1, it is characterized in that, the microwave antigen retrieval that step (5) is described, being about to histotomy is dipped in the antigen retrieval liquid of sodium citrate, trisodium citrate and pure water preparation, in micro-wave oven, the heating of high fire screen is 3 minutes, then in low fire screen heating 4 minutes * 2 times, cooling under room temperature after taking out, with the washing of PBS damping fluid, 5 minutes * 3 times.
3. method as claimed in claim 2, it is characterized in that, the deactivating endogenous peroxydase that step (6) is described, the deactivation liquid being made into by 1:9 with 30% hydrogen peroxide and methyl alcohol, histotomy is immersed in deactivation liquid to 30 minutes, after deactivating endogenous peroxydase, with the washing of PBS damping fluid, 5 minutes * 3 times.
4. method as claimed in claim 3, it is characterized in that, the described sealing nonspecific proteins of step (7) is about to histotomy scrub, and the confining liquid that drips 50 microlitres on every histotomy is 5% BSA aqueous solution, hatch sealing heterogenetic antigen 30 minutes.
5. method as claimed in claim 4, it is characterized in that, the described anti-soon section of dropping two of step (10) is inserted in wet box, with filter paper, tissue moisture is around sucked, the A liquid that every histotomy drips in the universal immunologic combined detection reagent kit of anti-rabbit/mouse is one, horseradish peroxidase polymkeric substance, under room temperature, hatches half an hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410169571.8A CN103954757B (en) | 2014-04-25 | 2014-04-25 | A kind of method colorectal cancer evaluated by TEAD4 nucleus positive expression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410169571.8A CN103954757B (en) | 2014-04-25 | 2014-04-25 | A kind of method colorectal cancer evaluated by TEAD4 nucleus positive expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103954757A true CN103954757A (en) | 2014-07-30 |
| CN103954757B CN103954757B (en) | 2016-08-24 |
Family
ID=51332056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410169571.8A Expired - Fee Related CN103954757B (en) | 2014-04-25 | 2014-04-25 | A kind of method colorectal cancer evaluated by TEAD4 nucleus positive expression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103954757B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113466458A (en) * | 2021-06-29 | 2021-10-01 | 复旦大学附属中山医院 | Application of GPX4, NOX1 and ACSL4 in colorectal cancer prognosis evaluation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040146921A1 (en) * | 2003-01-24 | 2004-07-29 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
| KR20090087432A (en) * | 2009-07-28 | 2009-08-17 | 한국생명공학연구원 | Colon cancer diagnostic markers using up-regulated genes |
-
2014
- 2014-04-25 CN CN201410169571.8A patent/CN103954757B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040146921A1 (en) * | 2003-01-24 | 2004-07-29 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
| KR20090087432A (en) * | 2009-07-28 | 2009-08-17 | 한국생명공학연구원 | Colon cancer diagnostic markers using up-regulated genes |
Non-Patent Citations (1)
| Title |
|---|
| 王进科: "《生物医学实验》", 31 July 2013, article "实验37 组织中蛋白表达的免疫组化检测" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113466458A (en) * | 2021-06-29 | 2021-10-01 | 复旦大学附属中山医院 | Application of GPX4, NOX1 and ACSL4 in colorectal cancer prognosis evaluation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103954757B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sofi et al. | Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement | |
| CN110187110B (en) | Cardiac cancer prognosis prediction marker and application thereof | |
| CN106153922A (en) | A kind of colon cancer prognosis prediction mark and detection method thereof | |
| CN102298053B (en) | Composite antibody kit used in postoperative recurrence risk assessment of primary hepatocellular carcinoma | |
| Ni et al. | TTF‐1 expression in breast carcinoma: an unusual but real phenomenon | |
| WO2023035728A1 (en) | Method for generating training data based on immunohistochemistry, and storage device | |
| CN103592444A (en) | Method for detecting cyclin G1 protein expression in breast cancer and carrying out prognosis evaluation | |
| CN103257229A (en) | Method for evaluating prognosis of colorectal cancer patient through positive expression quantity of colorectal cancer immunological index CD3 | |
| Shim et al. | Diagnostic algorithm for papillary urothelial tumors in the urinary bladder | |
| CN103278650A (en) | Method for evaluating prognosis of patients with colorectal cancers through positive expression of colorectal cancer immunological index CD45RO | |
| Teo et al. | Angiogenesis and invasive recurrence in ductal carcinoma in situ of the breast | |
| Min et al. | Diagnostic and prognostic relevance of Cullin1 expression in invasive ductal carcinoma of the breast | |
| Khatami et al. | Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy | |
| CN103954757A (en) | Method for evaluating colorectal cancer through TEAD4 positive cell nucleus expression conditions | |
| Lan et al. | Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors | |
| CN106908609A (en) | Purposes of the tumour-specific trnaplantation antigen albumen TSTA3 in oesophagus squama cancer diagnosis reagent is prepared | |
| CN105717104A (en) | Peripheral blood GPC3 detection method for hepatocellular carcinoma patient | |
| CN103926408A (en) | Kit for forecasting NSCLC (non-small-cell lung cancer) patient prognosis and application of osteopontin acting as specific marker | |
| CN106290895A (en) | CHKA albumen application, test kit and method in preparing prognosis in hcc assessment test kit | |
| CN103267849A (en) | Method for evaluating prognosis of patient with colorectal cancer by positive expression quantity of colorectal cancer immunology index CD8 | |
| CN105572388A (en) | Method for detecting peripheral blood circulating tumor cell EGFR of advanced rectal cancer patient | |
| CN103063850B (en) | Application of Shp2 protein in preparation of liver cancer prognosis evaluation kit | |
| CN105785004B (en) | Purposes of the CDC GAP-associated protein GAP 2 in diagnosis of pancreatic cancer or prognosis | |
| CN110320369B (en) | Kit for diagnosing bladder cancer | |
| CN111665358B (en) | Application of NALCN protein in prognosis prediction of esophageal squamous cell carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20180425 |